Minerva Neurosciences | NERV - Marktkapitalisierung





Marktkapitalisierung Veränderung Datum
Acadia Pharmaceuticals USD 3.57B 221M 2026-05
Adma Biologics USD 4.34B 845M 2025-12
ALKERMES USD 5.66B 217M 2026-05
Alterity Therapeutics Limited AUD 40M 16M 2026-05
AstraZeneca USD 301.25B 13.1B 2026-03
BioCryst Pharmaceuticals USD 1.66B 64M 2025-12
Bristol-Myers Squibb USD 123.83B 14.02B 2026-03
Cipla INR 1.15T 162.77B 2026-05
Clal Biotechnology ILS 43.45M 8.92M 2026-03
Compugen USD 144.67M 7.17M 2025-12
CSL USD 55.89B 20.42B 2025-12
Eli Lilly USD 869.02B 146.97B 2026-03
Esperion Therapeutics USD 885M 351M 2025-12
GlaxoSmithKline GBP 83.8B 9.44B 2026-03
Halozyme Therapeutics USD 8.56B 905M 2026-05
Ionis Pharmaceuticals USD 12.46B 356M 2026-03
J&J USD 579.15B 78.91B 2026-03
Merck USD 297.1B 35.84B 2026-03
Neurocrine Biosciences USD 15.15B 1.9B 2026-05
Novartis USD 232.75B 75B 2026-05
Novavax USD 1.09B 316M 2025-12
Pfizer USD 147.4B 6.42B 2026-05
Roche Holding CHF 266.34B 55.46B 2025-12
Sanofi EUR 100.27B 605.48M 2026-03
Takeda JPY 8.33T 681.01B 2026-05
Vanda Pharmaceuticals USD 279M 6M 2024-12